
Matthew Karr, DO, highlights advances in the CLL paradigm, current goals in researching CNS lymphoma, and other future directions in hematology/oncology.
When CML patients develop resistance or intolerance to these drugs, transplant may be the only option.
The need for allogeneic stem cell transplant in chronic myeloid leukemia (CML) patients has decreased due to tyrosine kinase inhibitor (TKI) use. But when CML patients develop resistance or intolerance to these drugs, transplant may be the only option.
This study was recently